Mesenchymal stem cells - Longeveron

Drug Profile

Mesenchymal stem cells - Longeveron

Alternative Names: Longeveron mesenchymal stem cells

Latest Information Update: 08 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Longeveron
  • Developer Longeveron; University of Miami
  • Class Antidementias; Stem cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Fatigue
  • Phase I Alzheimer's disease
  • Clinical Phase Unknown Metabolic syndrome

Most Recent Events

  • 15 May 2017 Longeveron plans a phase IIb trial for Asthenia
  • 01 Nov 2016 Phase-I/II clinical trials in Fatigue (In the elderly) in USA (IV) (NCT02982915)
  • 01 Aug 2016 Phase-I clinical trials in Alzheimer's disease in USA (IV) (NCT02600130)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top